AbbVie's Skyrizi Adds Crohn's Disease Indication In Europe

Skyrizi is the first specific IL-23 inhibitor for the treatment of Crohn's disease in Europe, though the drug was approved with a broader label in the US.

approval stamp — AbbVie's Skyrizi is cleared in Europe for Crohn's disease • Source: Shutterstock

AbbVie's big immunology growth-driver Skyrizi (risankizumab) has gained an expanded label in Europe with an approval for the treatment of Crohn's disease, following US approval for the indication in June. The company announced the European Commission approved Skyrizi on 23 November as the first specific IL-23 inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.